pioglitazone has been researched along with Cancer of Kidney in 6 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy." | 2.77 | Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. ( Andreesen, R; Berand, A; Bross, K; Grassinger, J; Reichle, A; Rogenhofer, S; Schrettenbrunner, I; Suedhoff, T; Vogelhuber, M; Walter, B; Wieland, WF; Wilke, J, 2012) |
| " None of the dose-response parameters showed a significant trend of risk association, with all P-trends >0." | 1.40 | Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes. ( Tseng, CH, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tseng, CH | 1 |
| Walter, B | 1 |
| Schrettenbrunner, I | 1 |
| Vogelhuber, M | 1 |
| Grassinger, J | 1 |
| Bross, K | 1 |
| Wilke, J | 1 |
| Suedhoff, T | 1 |
| Berand, A | 1 |
| Wieland, WF | 1 |
| Rogenhofer, S | 1 |
| Andreesen, R | 1 |
| Reichle, A | 1 |
| Mahmoud, MF | 1 |
| El Shazly, SM | 1 |
| Yuan, J | 1 |
| Takahashi, A | 1 |
| Masumori, N | 1 |
| Uchida, K | 1 |
| Hisasue, S | 1 |
| Kitamura, H | 1 |
| Itoh, N | 1 |
| Tsukamoto, T | 1 |
| Yang, FG | 1 |
| Zhang, ZW | 1 |
| Xin, DQ | 1 |
| Shi, CJ | 1 |
| Wu, JP | 1 |
| Guo, YL | 1 |
| Guan, YF | 1 |
| Inoue, K | 1 |
| Kawahito, Y | 1 |
| Tsubouchi, Y | 1 |
| Kohno, M | 1 |
| Yoshimura, R | 1 |
| Yoshikawa, T | 1 |
| Sano, H | 1 |
1 trial available for pioglitazone and Cancer of Kidney
| Article | Year |
|---|---|
Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Age | 2012 |
5 other studies available for pioglitazone and Cancer of Kidney
| Article | Year |
|---|---|
Pioglitazone does not affect the risk of kidney cancer in patients with type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Kidney Neoplasms; Male; | 2014 |
Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.
Topics: Animals; Benzhydryl Compounds; Carcinoma, Renal Cell; Cell Line, Tumor; Cisplatin; Epoxy Compounds; | 2013 |
Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cell Division; Dose-Response Relationship, Drug; Humans; Kidney Neoplasms; Pi | 2005 |
Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Chrom | 2005 |
Expression of peroxisome proliferator-activated receptor gamma in renal cell carcinoma and growth inhibition by its agonists.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Division; Chromans; Coloring A | 2001 |